FR3061716B1 - Nouveaux composes ciblant le cd160 humain - Google Patents
Nouveaux composes ciblant le cd160 humain Download PDFInfo
- Publication number
- FR3061716B1 FR3061716B1 FR1750152A FR1750152A FR3061716B1 FR 3061716 B1 FR3061716 B1 FR 3061716B1 FR 1750152 A FR1750152 A FR 1750152A FR 1750152 A FR1750152 A FR 1750152A FR 3061716 B1 FR3061716 B1 FR 3061716B1
- Authority
- FR
- France
- Prior art keywords
- seq
- human
- novel compounds
- compounds targeting
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
Abstract
La présente invention a pour objet de nouveaux composés qui se lient spécifiquement au CD160 humain, comprenant un domaine variable de chaîne légère (VL) une séquence choisie définie par SEQ ID No:14 ou SEQ ID No:13 et un domaine variable de chaîne lourde (VH) une séquence choisie parmi SEQ ID No:11, SEQ ID No:25, SEQ ID No: 26, SEQ ID No:27, SEQ ID No: 28, SEQ ID No:29 ou SEQ ID No:30 leurs fragments ou leurs dérivés.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1750152A FR3061716B1 (fr) | 2017-01-06 | 2017-01-06 | Nouveaux composes ciblant le cd160 humain |
US16/476,171 US10975159B2 (en) | 2017-01-06 | 2018-01-08 | Compounds binding human CD160 and uses thereof |
CA3048799A CA3048799A1 (fr) | 2017-01-06 | 2018-01-08 | Composes se liant au cd160 humain et leurs utilisations |
PCT/EP2018/050354 WO2018127586A1 (fr) | 2017-01-06 | 2018-01-08 | Composés se liant au cd160 humain et leurs utilisations |
CN201880016030.8A CN110381999B (zh) | 2017-01-06 | 2018-01-08 | 结合人cd160的化合物及其用途 |
JP2019536858A JP7189878B2 (ja) | 2017-01-06 | 2018-01-08 | ヒトcd160を結合する結合物及びその使用 |
EP18702410.4A EP3565593A1 (fr) | 2017-01-06 | 2018-01-08 | Composés se liant au cd160 humain et leurs utilisations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1750152 | 2017-01-06 | ||
FR1750152A FR3061716B1 (fr) | 2017-01-06 | 2017-01-06 | Nouveaux composes ciblant le cd160 humain |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3061716A1 FR3061716A1 (fr) | 2018-07-13 |
FR3061716B1 true FR3061716B1 (fr) | 2019-05-17 |
Family
ID=59325344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1750152A Active FR3061716B1 (fr) | 2017-01-06 | 2017-01-06 | Nouveaux composes ciblant le cd160 humain |
Country Status (7)
Country | Link |
---|---|
US (1) | US10975159B2 (fr) |
EP (1) | EP3565593A1 (fr) |
JP (1) | JP7189878B2 (fr) |
CN (1) | CN110381999B (fr) |
CA (1) | CA3048799A1 (fr) |
FR (1) | FR3061716B1 (fr) |
WO (1) | WO2018127586A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113613664A (zh) * | 2019-03-01 | 2021-11-05 | 阿奇洛伊斯生物制药公司 | 在抗原特异性免疫细胞中调节cd160功能的方法及其用途 |
GB202103706D0 (en) * | 2021-03-17 | 2021-04-28 | Ucl Business Ltd | CD160 binding domain |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998021240A1 (fr) | 1996-11-12 | 1998-05-22 | Dana-Farber Cancer Institute | Proteine by55 recombinee et acides nucleiques la codant |
JP4563171B2 (ja) * | 2002-05-24 | 2010-10-13 | シェーリング コーポレイション | 中和ヒト抗igfr抗体 |
JP2007528723A (ja) * | 2003-08-22 | 2007-10-18 | メディミューン,インコーポレーテッド | 抗体のヒト化 |
EP1626059A1 (fr) * | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Applications angiogéniques et immunologiques de composés spécifiques anti-CD160 pouvant être obtenus à partir de l'anticorps monoclonal CL1-R2 |
WO2006031825A2 (fr) * | 2004-09-13 | 2006-03-23 | Macrogenics, Inc. | Anticorps humanises contre le virus du nil occidental ainsi qu'utilisations therapeutiques et prophylactiques associees |
WO2006033386A1 (fr) * | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | Anticorps igg4 humains stabilises |
EP2006299A1 (fr) | 2007-06-18 | 2008-12-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Identification de nouveaux isoformes du récepteur CD160 spécifique de classe I MHC et utilisations associées |
EP2210903A1 (fr) * | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anticorps monoclonaux anti-CD 160 et leurs utilisations |
CN102892432A (zh) * | 2010-05-28 | 2013-01-23 | 国家医疗保健研究所 | 用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体 |
EP2455403A1 (fr) * | 2010-11-23 | 2012-05-23 | Pierre Fabre Medicament | Anticorps humanisés homogènes contre JAM-A qui inhibitent la prolifération |
WO2012096994A2 (fr) * | 2011-01-10 | 2012-07-19 | Emory University | Anticorps dirigés contre le virus de la grippe |
CA2852474A1 (fr) * | 2011-10-18 | 2013-04-25 | Emory University | Anticorps antigrippaux |
MX2015015232A (es) * | 2013-05-02 | 2016-02-22 | Ares Trading Sa | Anticuerpo monoclonal dirigido contra cxcr5. |
RU2718692C2 (ru) * | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
US20180030118A1 (en) * | 2015-02-19 | 2018-02-01 | Emergent Biosolutions Canada Inc. | Humanzied filovirus antibodies and uses thereof |
TW201710286A (zh) * | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
AU2016383475B2 (en) * | 2015-12-28 | 2024-02-22 | Innate Pharma | Variable regions for NKp46 binding proteins |
-
2017
- 2017-01-06 FR FR1750152A patent/FR3061716B1/fr active Active
-
2018
- 2018-01-08 EP EP18702410.4A patent/EP3565593A1/fr active Pending
- 2018-01-08 CA CA3048799A patent/CA3048799A1/fr active Pending
- 2018-01-08 JP JP2019536858A patent/JP7189878B2/ja active Active
- 2018-01-08 CN CN201880016030.8A patent/CN110381999B/zh active Active
- 2018-01-08 WO PCT/EP2018/050354 patent/WO2018127586A1/fr unknown
- 2018-01-08 US US16/476,171 patent/US10975159B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3048799A1 (fr) | 2018-07-12 |
FR3061716A1 (fr) | 2018-07-13 |
EP3565593A1 (fr) | 2019-11-13 |
CN110381999A (zh) | 2019-10-25 |
JP7189878B2 (ja) | 2022-12-14 |
US20200109211A1 (en) | 2020-04-09 |
US10975159B2 (en) | 2021-04-13 |
WO2018127586A1 (fr) | 2018-07-12 |
JP2020505013A (ja) | 2020-02-20 |
CN110381999B (zh) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
CY1120665T1 (el) | Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους | |
CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
CU20190099A7 (es) | Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo | |
MX2022000112A (es) | Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3). | |
EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
CY1124630T1 (el) | Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνης | |
JP2018504907A5 (fr) | ||
EA202191763A1 (ru) | Бифункциональная молекула анти-pd-1/sirp | |
MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
PH12021550244A1 (en) | Anti-btla antibody | |
EA201991353A1 (ru) | Двухвалентные антитела, маскированные спирализованными спиралями | |
EA201992756A3 (ru) | Антитела против cd48 и их конъюгаты | |
EP4282434A3 (fr) | Anticorps, leurs utilisations et leurs conjugués | |
MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
PE20230381A1 (es) | Proteina de union a rgma | |
MX2020007880A (es) | Anticuerpos de mica/b y metodos de uso. | |
PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
CY1121950T1 (el) | Νεα αντισωματα εναντι φωσφορυλχολινης | |
MX2022015129A (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso. | |
MX2021001254A (es) | Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso. | |
EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20180713 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |